BG NE1
Alternative Names: AML neoantigen - Guangzhou Bio-gene Technology; BG-NE1Latest Information Update: 28 Jan 2024
Price :
$50 *
At a glance
- Originator Guangzhou Bio-gene Technology
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in China
- 05 Dec 2019 BG NE1 is available for licensing as of 05 Dec 2019. http://www.gzbiogene.com/english.php/
- 01 Dec 2019 Preclinical trials in Acute myeloid leukaemia in China before December 2019 (Guangzhou Bio-gene Technology pipeline, December 2019)